Platelet Concentrates

Their action follows a coordinated sequence at the site of vascular injury. Platelets adhere to the damaged vessel wall, become activated, and aggregate with one another. This growing platelet mass helps form an initial plug, while the activated cells also provide a surface that supports coagulation. Together, these processes reinforce clot formation where bleeding has occurred.

Activated platelets do more than accumulate at an injury. They create a surface that supports coagulation reactions, linking the early platelet plug with the processes that strengthen the clot. This matters when bleeding reflects inadequate platelet numbers or function, because transfused cells can help restore both the cellular plug and the environment needed for more stable clot formation.

After activation, platelets release mediators that reinforce clot formation and support communication among components of the hemostatic response. Their release complements adhesion and aggregation rather than replacing them. Consequently, the transfused cells can contribute through several coordinated actions: attachment to injury, accumulation into a plug, coagulation support, and chemical reinforcement of the developing clot.

Preparation can begin with donated whole blood or with direct collection by apheresis, a process that selectively collects platelets from the donor. The resulting component contains platelets suspended in plasma and is then maintained under controlled storage conditions before transfusion. These preparation routes provide platelet-containing components for clinical use while preserving the plasma environment in which the cells are suspended.

They may be considered when a patient has thrombocytopenia, meaning an inadequate platelet number, or platelet dysfunction, meaning impaired platelet performance. The overview identifies use in patients receiving chemotherapy, undergoing major surgery, or experiencing serious bleeding. In each setting, the clinical purpose is to address insufficient platelet-mediated hemostasis, while the decision remains dependent on the patient’s clinical need.

A transfusion decision requires more than identifying a low platelet number or a bleeding event. Clinicians must consider the clinical need together with compatibility and safety. These considerations help determine whether administration is appropriate for the individual situation and support responsible use of the component, particularly in patients with chemotherapy-related risks, major surgical needs, or serious bleeding.